Lumentum stock sinks 8% after tech-led slide — what traders watch next

Lumentum stock sinks 8% after tech-led slide — what traders watch next

New York, Jan 14, 2026, 19:29 EST — After-hours

  • Lumentum shares ended the day down 8.2%, edging up just a bit in after-hours trading
  • Nasdaq dropped 1%, weighed down by losses in banks and big tech stocks
  • Attention turns to Lumentum’s Feb. 3 earnings and if it can meet its guidance

Lumentum Holdings’ stock plunged 8.2% on Wednesday, closing at $331.62 before nudging higher to around $332 in after-hours trading. (MarketWatch)

This move is significant as Lumentum has ranked among the most crowded “AI infrastructure” plays. Yet the tape has turned against pricey winners. With earnings season kicking off, investors are faster to slash risk amid broader market jitters.

No fresh company news explained the slide. Traders are left to sift through the selloff in tech, a stock that surged into January, and an upcoming earnings report that might either steady things or fan the flames of the retreat.

Wall Street edged lower Wednesday, dragged down by bank and Big Tech shares despite more stocks gaining than losing. The S&P 500 slipped 0.5%, while the Nasdaq tumbled 1%. Wells Fargo sank 4.6%, and Broadcom dropped 4.2%, according to an AP report. (AP News)

Lumentum’s shares fluctuated from $327.50 up to $363 in the session, with roughly 3.7 million shares traded, according to market data.

The stock has swung sharply this month, after hitting an all-time peak near $402 early in January, according to Investing.com. (Investing)

Lumentum produces optical and photonics components for telecom, enterprise, and data center networks—sectors investors link directly to the recent spike in AI computing investments. (Lumentum)

Lumentum plans to report its fiscal second-quarter results on Feb. 3, right after the market closes. The company will hold a webcast at 5 p.m. ET that day, it announced. (Business Wire)

Lumentum reported revenue of $533.8 million and non-GAAP EPS of $1.10 in its latest quarterly filing. The company expects fiscal second-quarter revenue between $630 million and $670 million, with non-GAAP EPS projected from $1.30 to $1.50. CEO Michael Hurlston noted that revenue, operating margin, and EPS “came in at the high end of our guidance ranges.” (Business Wire)

But the setup works both ways. A stock valued for rapid expansion can tumble quickly if major cloud clients pull back on orders, margins shrink, or the management’s guidance slips even a bit.

Thursday’s session will test if the broader tech selloff keeps momentum and if high-beta AI-adjacent names like Lumentum attract buyers after the recent pause. The key date to mark is Feb. 3, when Lumentum reports earnings and fields questions live.

Stock Market Today

  • Moderna advances as market slides ahead of earnings; Zacks Rank holds
    January 14, 2026, 7:52 PM EST. Moderna (MRNA) closed at $41.66, up 0.6% as broad market weakness weighed on peers. The stock outpaced the S&P 500, which fell 1.46%, while the Dow rose 0.65% and the Nasdaq sank 3.07%. Over the last month, MRNA has risen about 3.19%, beating the Medical sector's 1.84% gain and the S&P 500's 1.08%. Investors await the company's upcoming earnings report. The consensus calls for an EPS of -$2.94, a 634.55% year-over-year drop, and revenue of $956.79 million, down 65.96%. The Zacks Rank stands at #3 (Hold), with the Consensus EPS estimate 0.71% lower in the past month. The Medical - Biomedical and Genetics industry sits at Zacks Industry Rank 70, in the top 28% of more than 250 groups.
AbbVie stock in focus after hours as it eyes obesity market — what to watch next
Previous Story

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

Circle stock (CRCL) rises after-hours as stablecoin regulation battle returns to Washington
Next Story

Circle stock (CRCL) rises after-hours as stablecoin regulation battle returns to Washington

Go toTop